Merck reports Phase II data for Keytruda as first-line RCC therapy

Merck & Co. Inc. (NYSE:MRK) reported interim data from 110 evaluable patients with advanced clear cell renal cell carcinoma (RCC)

Read the full 204 word article

User Sign In